Innovotech Inc. Announces CFO Transition and AGM Results
Edmonton, Alberta — June 16, 2026 — Leads & Copy — Innovotech Inc. (TSXV: IOT; OTCQB: IOTCF), a life sciences services and technology company, announced a transition in its Chief Financial Officer role and provided an update on its 2026 Annual General Meeting (AGM) results. Bernard Grobbelaar has concluded his tenure as CFO, and Craig Kalvin has been appointed as the Company’s new CFO, effective immediately.
Mr. Grobbelaar served as CFO during a significant development period for Innovotech, which included the acquisition and integration of Keystone Labs and the reinforcement of the Company’s financial infrastructure. The Company extended its gratitude to Mr. Grobbelaar for his contributions and leadership, wishing him success in his future endeavors. His work is credited with positioning Innovotech for its subsequent phase of growth.
The Board of Directors welcomed Mr. Kalvin, who brings extensive experience in financial leadership. His background includes serving as CFO for a prominent mining company and several high-growth technology firms. He possesses strong expertise in IFRS reporting, governance, and financial planning, and has guided companies through periods of expansion, change, and operational scaling.
Craig Milne, Chief Executive Officer of Innovotech, commented on the transition: “We thank Bernard for his dedication and the important role he has played in building a strong financial foundation for Innovotech. We are very pleased to welcome Craig Kalvin as our new CFO. Craig will bring fresh leadership around our financial discipline. As we continue our transformation, we believe his judgement and pragmatism will be critical in translating strategy into disciplined execution and long‑term value creation.”
Regarding the AGM results, shareholders voted in favor of all proposed matters. These included the re-election of James Timourian, Karen Farkas, David Tam, Julie Wright, Brad Clark, Arden Tse, and Craig Milne as directors of the Company. Shareholders also approved the appointment of D&H Group LLP as the Company’s auditors for the upcoming fiscal year and the continuation of the Omnibus Security Based Compensation Plan, which was initially adopted in 2024.
In other developments, the Board of Directors is pleased to announce the appointment of Mr. Tse as Vice Chair of the Board.
Innovotech Inc. is an established and growing life sciences services and technology company that specializes in contract research, analytical, and microbial testing within regulated healthcare markets. The Company is recognized for its leadership in biofilm science and antimicrobial testing, offering advanced laboratory services that support the development of medical devices, pharmaceuticals, and industrial products. Innovotech combines scientific expertise with proprietary methods and products, such as its widely used MBEC Assay® platform for high-throughput antimicrobial and antibiotic testing. Operating through ISO-certified and GMP-accredited laboratories, Innovotech supports clients across various sectors and geographic regions, delivering dependable data that aligns with regulatory expectations from agencies including the U.S. Food and Drug Administration and Health Canada. More information is available at https://www.innovotech.ca.
Source: Innovotech Inc.
Share this story:
